ViewRay, Inc. (VRAY): Price and Financial Metrics

ViewRay, Inc. (VRAY): $0.03

0.02 (-39.90%)

POWR Rating

Component Grades








VRAY Price/Volume Stats

Current price $0.03 52-week high $4.96
Prev. close $0.04 52-week low $0.02
Day low $0.02 Volume 108,502,700
Day high $0.04 Avg. volume 7,510,055
50-day MA $0.43 Dividend yield N/A
200-day MA $2.97 Market Cap 4.59M

VRAY Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where VRAY ranks best; there it ranks ahead of 66.46% of US stocks.
  • The strongest trend for VRAY is in Value, which has been heading up over the past 149 days.
  • VRAY's current lowest rank is in the Stability metric (where it is better than 5.52% of US stocks).

VRAY Stock Summary

  • Revenue growth over the past 12 months for VIEWRAY INC comes in at 44.09%, a number that bests 85.69% of the US stocks we're tracking.
  • The volatility of VIEWRAY INC's share price is greater than that of 94.83% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VRAY comes in at -26.61% -- higher than that of just 15.47% of stocks in our set.
  • Stocks that are quantitatively similar to VRAY, based on their financial statements, market capitalization, and price volatility, are OM, TBLA, PHR, MXCT, and CRCT.
  • VRAY's SEC filings can be seen here. And to visit VIEWRAY INC's official web site, go to

VRAY Valuation Summary

  • VRAY's price/sales ratio is 0.6; this is 87.5% lower than that of the median Healthcare stock.
  • Over the past 88 months, VRAY's price/earnings ratio has gone up 3.

Below are key valuation metrics over time for VRAY.

Stock Date P/S P/B P/E EV/EBIT
VRAY 2023-06-28 0.6 1.2 -0.6 -0.6
VRAY 2023-06-27 0.7 1.3 -0.6 -0.6
VRAY 2023-06-26 0.7 1.3 -0.7 -0.7
VRAY 2023-06-23 0.7 1.3 -0.6 -0.6
VRAY 2023-06-22 0.6 1.2 -0.6 -0.6
VRAY 2023-06-21 0.7 1.4 -0.7 -0.7

VRAY Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 280.75%.
  • The 5 year revenue growth rate now stands at 353.95%.
  • Its 3 year cash and equivalents growth rate is now at 25.46%.
Over the past 49 months, VRAY's revenue has gone up $7,683,000.

The table below shows VRAY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 87.902 -74.412 -106.582
2022-06-30 80.589 -76.112 -105.736
2022-03-31 73.47 -68.169 -109.079
2021-12-31 70.119 -62.091 -110.048
2021-09-30 68.189 -60.183 -109.079
2021-06-30 59.098 -58.768 -111.943

VRAY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VRAY has a Quality Grade of F, ranking ahead of 4.3% of graded US stocks.
  • VRAY's asset turnover comes in at 0.212 -- ranking 141st of 186 Medical Equipment stocks.
  • DXCM, SRTS, and SMTI are the stocks whose asset turnover ratios are most correlated with VRAY.

The table below shows VRAY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.212 -0.038 -0.931
2021-03-31 0.204 -0.028 -0.887
2020-12-31 0.194 -0.071 -0.869
2020-09-30 0.174 -0.148 -0.903
2020-06-30 0.218 -0.099 -0.769
2020-03-31 0.278 -0.027 -0.752

VRAY Price Target

For more insight on analysts targets of VRAY, see our VRAY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.88 Average Broker Recommendation 1.29 (Strong Buy)

ViewRay, Inc. (VRAY) Company Bio

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems worldwide. It offers MRIdian, a MRI-guided radiation therapy system that images and treats cancer patients simultaneously. MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. The company markets its MRIdian through a direct sales force in the United States and distributors worldwide to a range of customers, including university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. was founded in 2004 and is based in Oakwood Village, Ohio.

VRAY Latest News Stream

Event/Time News Detail
Loading, please wait...

VRAY Latest Social Stream

Loading social stream, please wait...

View Full VRAY Social Stream

Latest VRAY News From Around the Web

Below are the latest news stories about VIEWRAY INC that investors may wish to consider to help them evaluate VRAY as an investment opportunity.

VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System

ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center. This will be the first cancer center in Oklahoma and the fourth VA medical center offering Veterans access to MRIdian's advanced MRI-guided radiation therapy to treat cancer. The MRIdian system will enable the Oklahoma City VA Medical Center to provide precision MRI-guided rad

Yahoo | June 13, 2023

Do You Believe in the Growth Prospects of ViewRay (VRAY)?

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The fund was up 11.20% in the first quarter compared to the Russell 2000 Growth Index’s return of 6.07%. The strong performance of holdings in the Information Technology (IT), Industrials, and […]

Yahoo | May 16, 2023

ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting

ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) with over 50 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 12-16, 2023, in Vienna, Austria.

Yahoo | May 12, 2023

Need To Know: The Consensus Just Cut Its ViewRay, Inc. (NASDAQ:VRAY) Estimates For 2023

The latest analyst coverage could presage a bad day for ViewRay, Inc. ( NASDAQ:VRAY ), with the analysts making...

Yahoo | May 12, 2023

Q1 2023 ViewRay Inc Earnings Call

Q1 2023 ViewRay Inc Earnings Call

Yahoo | May 11, 2023

Read More 'VRAY' Stories Here

VRAY Price Returns

1-mo N/A
3-mo -92.09%
6-mo -99.10%
1-year -99.19%
3-year -99.05%
5-year -99.68%
YTD -99.33%
2022 -18.69%
2021 44.24%
2020 -9.48%
2019 -30.48%
2018 -34.45%

Continue Researching VRAY

Here are a few links from around the web to help you further your research on ViewRay Inc's stock as an investment opportunity:

ViewRay Inc (VRAY) Stock Price | Nasdaq
ViewRay Inc (VRAY) Stock Quote, History and News - Yahoo Finance
ViewRay Inc (VRAY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!